Rosalind Advisors Inc's Q2 2026 13F: 3 new positions, 6 exits
Form 13F-HR for the quarter ended Jun 30, 2026 · filed Aug 14, 2026 · 29 reported positions · accession 0001622627-26-000022
What changed this quarter
| Activity | Security | Weight before | Weight now | Change | Shares | Shares % |
|---|---|---|---|---|---|---|
| Exited | CG ONCOLOGY INC (CGON) | 2.8% | — | −2.8 pts | −100K sh | −100% |
| Increased | VERASTEM INC (VSTM) | 4.6% | 5.7% | +1.1 pts | +1.85M sh | +86% |
| Exited | VIRIDIAN THERAPEUTICS INC (VRDN) | 2.0% | — | −2.0 pts | −250K sh | −100% |
| Reduced | VAXCYTE INC (PCVX) | 6.9% | 4.4% | −2.5 pts | −90,000 sh | −31% |
| Reduced | CELLDEX THERAPEUTICS INC (CLDX) | 4.3% | 2.8% | −1.5 pts | −130K sh | −39% |
| Increased | FENNEC PHARMACEUTICALS INC (FENC) | 7.3% | 12.9% | +5.5 pts | +280K sh | +10% |
| Increased | CYBIN INC (CYBN) | 3.0% | 4.9% | +1.8 pts | +425K sh | +28% |
| New | ABIVAX SA (ABVX) | — | 1.0% | +1.0 pts | +20,869 sh | new |
| Exited | DEFINIUM THERAPEUTICS INC (DFTX) | 1.0% | — | −1.0 pts | −125K sh | −100% |
| Reduced | XERIS BIOPHARMA HOLDINGS INC (XERS) | 7.7% | 8.7% | +1.0 pts | −323K sh | −10% |
| Reduced | BIOCRYST PHARMACEUTICALS INC (BCRX) | 3.6% | 2.7% | −0.9 pts | −202K sh | −22% |
| Exited | LIPOCINE INC (LPCN) | 0.7% | — | −0.7 pts | −222K sh | −100% |
| Increased | TALPHERA INC (TLPH) | 1.0% | 2.0% | +1.0 pts | +1.82M sh | +54% |
| Increased | REGENTIS BIOMATERIALS LTD (RGNT) | 0.3% | 0.9% | +0.6 pts | +450K sh | +179% |
| Reduced | ONKURE THERAPEUTICS INC (OKUR) | 0.8% | 0.3% | −0.5 pts | −294K sh | −66% |
| Increased | NEURAXIS INC (NRXS) | 0.7% | 1.1% | +0.4 pts | +222K sh | +78% |
| Exited | AVALO THERAPEUTICS INC (AVTX) | 0.5% | — | −0.5 pts | −75,000 sh | −100% |
| Exited | ANNEXON INC (ANNX) | 0.5% | — | −0.5 pts | −200K sh | −100% |
| New | SPRUCE BIOSCIENCES INC (SPRB) | — | 0.4% | +0.4 pts | +20,000 sh | new |
| Reduced | POLYPID LTD (PYPD) | 1.1% | 0.7% | −0.3 pts | −208K sh | −35% |
| Reduced | VOR BIOPHARMA INC (VOR) | 5.1% | 4.5% | −0.6 pts | −51,400 sh | −7% |
| Reduced | EYEPOINT PHARMACEUTICALS INC (EYPT) | 5.5% | 5.3% | −0.2 pts | −48,507 sh | −5% |
| New | PEPGEN INC (PEPG) | — | 0.2% | +0.2 pts | +350K sh | new |
| Reduced | ATEA PHARMACEUTICALS INC (AVIR) | 2.6% | 1.9% | −0.7 pts | −101K sh | −9% |
| Reduced | MYOMO INC (MYO) | 1.1% | 1.4% | +0.4 pts | −209K sh | −5% |
| Reduced | SAVARA INC (SVRA) | 7.2% | 7.4% | +0.2 pts | −25,600 sh | −1% |
| Increased | BIOFRONTERA INC (BFRI) | 0.4% | 0.5% | +0.1 pts | +112K sh | +10% |
Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled
Top 10 positions — 74.9% of the equity book
Changes in the top 10 this quarter: CYBN entered · MDWD left
| # | Security | Weight before | Weight now | |
|---|---|---|---|---|
| 1 | DELCATH SYSTEMS, INC. (DCTH) | 12.5% | 15.6% | |
| 2 | FENNEC PHARMACEUTICALS INC (FENC) | 7.3% | 12.9% | |
| 3 | XERIS BIOPHARMA HOLDINGS INC (XERS) | 7.7% | 8.7% | |
| 4 | SAVARA INC (SVRA) | 7.2% | 7.4% | |
| 5 | VERASTEM INC (VSTM) | 4.6% | 5.7% | |
| 6 | X4 PHARMACEUTICALS INC (XFOR) | 5.4% | 5.6% | |
| 7 | EYEPOINT PHARMACEUTICALS INC (EYPT) | 5.5% | 5.3% | |
| 8 | CYBIN INC (CYBN) | 3.0% | 4.9% | Entered the top 10 |
| 9 | VOR BIOPHARMA INC (VOR) | 5.1% | 4.5% | |
| 10 | VAXCYTE INC (PCVX) | 6.9% | 4.4% | |
| — | MEDIWOUND LTD (MDWD) | 4.9% | 4.1% | Left the top 10 |
Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).
Option positions (puts and calls)
Reported separately from the positions above. The value a 13F reports for an option is that of the underlying shares, not the option itself.
| Activity | Security | Type | Shares before | Shares now | Reported value |
|---|---|---|---|---|---|
| Exited | REPLIMUNE GROUP INC (REPL) | Call | 1.28M | 0 | $0 |
| New | SELLAS LIFE SCIENCES GROUP INC (SLS) | Put | 0 | 569K | $2.3M |
| Exited | INVESCO QQQ TR (QQQ) | Put | 250K | 0 | $0 |
| Exited | SPDR S&P 500 ETF TR (SPY) | Put | 125K | 0 | $0 |
| New | CG ONCOLOGY INC (CGON) | Call | 0 | 31,000 | $375K |
| New | EYEPOINT PHARMACEUTICALS INC (EYPT) | Call | 0 | 50,300 | $131K |
| New | ISHARES TR (NYC) | Put | 0 | 500K | $110K |
| Exited | VIRIDIAN THERAPEUTICS INC (VRDN) | Put | 264K | 0 | $0 |
| New | SPDR SERIES TRUST (BIL) | Put | 0 | 141K | $35.2K |
| New | TENAX THERAPEUTICS INC (TENX) | Put | 0 | 6,200 | $14K |
| Exited | UNIQURE NV (QURE) | Call | 296K | 0 | $0 |
| Exited | ARRIVENT BIOPHARMA INC (AVBP) | Call | 109K | 0 | $0 |